ALVEO Technologies

platform company focused on developing cloud-based diagnostic

Miacom was founded in 2007 with the mission to develop a novel and rapid diagnostic platform that will help physicians deliver timely and targeted antibiotic therapy decisions for critical care patients. Its multiplex assays identify and differentiate most of microorganisms causing life threatening conditions such as sepsis and pneumonia.

The rapid identification of microorganisms will help improve patient outcomes, reduce healthcare costs associated with lengthy hospitalizations, slow down the spread of antibiotic resistance among patients and most importantly save lives. Miacom’s multiplex assays can identify up to 14 clinically relevant pathogens causing sepsis and pneumonia. Clinical samples such as positive blood culture and sputum can be used directly in our tests and the time to results is just 30 minutes.

Milestones:

  • 2012: Stealth mode development of technology
  • 2017: Conducted series A financing
  • Participated in direct investment

contact

Silversky GmbH

Brunnenstrasse 23 40223 Düsseldorf
Germany

E-Mail: info@silversky-lifesciences.com

Impressum | Datenschutz

WRITE US AN EMAIL